- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04025372
INTREPId (INTermediate Risk Erection PreservatIon Trial)
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
In this research study, the investigators are looking at whether the novel form of hormonal therapy, called Darolutamide, when paired with radiation therapy will provide the same quality of care as the current standard treatments available for men with this type of cancer. Darolutamide prevents testosterone from signaling throughout the body. Although studies have shown that Darolutamide has activity in more advanced forms of prostate cancer, the activity of Darolutamide is unknown in intermediate risk prostate cancer treated with radiation therapy. The U.S. Food and Drug Administration (FDA) has not approved Darolutamide as a treatment for any disease.
The current standard of care treatments available to men with this type of cancer are radiation therapy with or without androgen deprivation therapy (ADT) involving a gonadotropin releasing hormone agonist plus bicalutamide (both FDA-approved) or surgery. ADT works by depriving the body of testosterone which "feeds" prostate cancer cells and weakens prostate cancer cells from repairing damage caused by radiation therapy.
In addition, the investigator will be assessing erectile function at baseline, during and after treatment to determine if short-term erectile function can be preserved without sacrificing long-term disease control.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Grace Pratt
- Phone Number: 617-582-8919
- Email: gkpratt@bwh.harvard.edu
Study Contact Backup
- Name: Martin T. King, MD, PhD
- Phone Number: 617-582-8919
- Email: Mtking@partners.org
Study Locations
-
-
Connecticut
-
Stamford, Connecticut, United States, 06904
- Recruiting
- Stamford Hospital
-
Contact:
- Anthony Gulati, MD
- Email: AGulati@stamhealth.org
-
Principal Investigator:
- Anthony Gulati, MD
-
-
Florida
-
Panama City, Florida, United States, 32405
- Recruiting
- Florida Cancer Affiliates
-
Contact:
- Steven Finkelstein, MD
- Email: steven.finkelstein@usoncology.com
-
Principal Investigator:
- Steven Finkelstein, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
Contact:
- Martin King, MD, PhD
- Email: Mtking@partners.org
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women Hospital
-
Principal Investigator:
- Martin T. King, MD, PhD
-
Contact:
- Martin T. King, MD, PhD
- Email: Mtking@partners.org
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Beth Israel Deaconness Medical Center
-
Contact:
- Glenn Bubley, MD, PhD
- Email: gbubley@bidmc.harvard.edu
-
Principal Investigator:
- Glenn Bubley, MD
-
Milford, Massachusetts, United States, 01757
- Recruiting
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
-
Contact:
- Peter F. Orio, DO, MS
- Phone Number: 508-488-3800
- Email: Peter_Orio@dfci.harvard.edu
-
Principal Investigator:
- Peter F. Orio, DO, MS
-
South Weymouth, Massachusetts, United States, 02190
- Recruiting
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
-
Contact:
- Peter F Orio, DO, MS
- Phone Number: 508-488-3800
- Email: Peter_Orio@dfci.harvard.edu
-
Principal Investigator:
- Peter F Orio, DO, MS
-
-
Missouri
-
Saint Louis, Missouri, United States, 63108
- Recruiting
- Washington University School of Medicine in St. Louis
-
Contact:
- Jeff Michalski, MD
- Email: jmichalski@wustl.edu
-
Principal Investigator:
- Jeff Michalski, MD
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Recruiting
- XCancer Omaha / Urology Cancer Center
-
Principal Investigator:
- Luke Nordquist, MD
-
Contact:
- Luke T Nordquist, MD
- Phone Number: 402-991-8468
- Email: drnordquist@gucancer.com
-
-
New York
-
Garden City, New York, United States, 11530
- Recruiting
- NYU Long Island
-
Contact:
- Aaron Katz, MD
- Phone Number: 516-535-1900
- Email: Aaron.Katz@nyulangone.org
-
Principal Investigator:
- Aaron Katz, MD
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Health
-
Principal Investigator:
- Aaron Katz, MD
-
Contact:
- Aaron Katz, MD
- Email: aaron.katz@nyulangone.org
-
Syracuse, New York, United States, 13210
- Recruiting
- Associated Medical Professionals of NY
-
Principal Investigator:
- Christopher Pieczonka, MD
-
Contact:
- Christopher Pieczonka, MD
- Email: cpieczonka@ampofny.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed prostate adenocarcinoma by biopsy within 1 year (365 days) from registration. The most recent biopsy will determine eligibility
- National Cancer Center Network (NCCN) intermediate risk prostate cancer, defined as clinical T2b-T2c, Gleason 7, or PSA 10-20 ng/mL. Patients who only have radiographic evidence of T3 disease (i.e. extracapsular extension, or seminal vesical invasion radiographically) will not be excluded.
Able to characterize the number of unfavorable intermediate risk factors below:
2-3 intermediate risk factors
- T2b-T2c
- Gleason 7
- PSA 10-20 ng/mL
- Gleason 4+3 disease
- Percent positive cores ≥ 50%
- Tissue available for submission for Decipher genomic score from archived tissue. Patients who had tissue sent to Decipher but did not have sufficient tissue for processing will not be excluded. Patients who already have a Decipher score must present official report documentation.
- Able to undergo radiation therapy with curative intent
- Age ≥ 18 at the time of consent.
- Demonstrate adequate organ function (hematologic, renal, hepatic) within 3 months of registration
- System Laboratory Value
Hematological:
- Platelet count (plt) ≥ 100,000/ µL
- Hemoglobin (Hgb) ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1000 cells/µL
Renal:
Glomerular filtration rate (GFR) ≥ 45 mL/min
- CKD-EPI equation will be used to calculate GFR
Hepatic and Other:
Bilirubin ≤ 1.5 × upper limit of normal (ULN)
- In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤1.5 × ULN, subject may be eligible
- Aspartate aminotransferase (AST) ≤ 2.5 × ULN
- Alanine aminotransferase (ALT) ≤ 2.5 × ULN
- Serum Albumin > 3.0 g/dL
- Serum potassium ≥ 3.5 mmol/L
Endocrine:
- Testosterone ≥ 150 ng/dL
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Good erectile function, as assessed by 'firm enough for masturbation or foreplay' or 'firm enough for intercourse' response to the question "How would you describe the usual quality of your erections during the past 4 weeks" on the EPIC-26 questionnaire
- Agrees to use a condom and another effective method of birth control if he is having sex with a woman of childbearing potential (defined as a premenopausal female capable of becoming pregnant) OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. It is recommended that men who have had a vasectomy more than a year prior to trial registration use a condom. Must also agree not to donate sperm.
- Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee
- Written informed consent and HIPAA authorization for release of personal health information prior to registration. Note: HIPAA authorization may be included in the informed consent or obtained separately. Subject must have the ability to understand and willingness to sign the written informed consent document.
- Ability to swallow pills.
- For patients in whom SBRT/combination RT stratification is pre-specified, prostate volume as determined by MRI, CT, or ultrasound to be less than 90 cc.
Exclusion Criteria:
- Prior surgical, cryotherapy, or high-intensity focused ultrasound for prostate cancer
- Prior orchiectomy or hormonal therapy (gonadotropin releasing hormone (GnRH) agonists, non-steroidal anti-androgens)
- Prior treatment with a first generation AR inhibitor (e.g. bicalutamide, flutamide, nilutamide, cyproterone acetate) or second generation AR inhibitor (e.g.Enzalutamide, Apalutamide, or Darolutamide)
- Prior treatment with other investigational AR inhibitors, CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700, or oral ketoconazole longer than 28 days
- Prior use of estrogens; patients who have used testosterone injections must have ceased utilization within 90 days prior to screening testosterone. Patients who have used any other type of testosterone supplementation (e.g. patches) must have ceased utilization within 45 days prior to screening testosterone.
- Use of 5-α reductase inhibitors (finasteride, dutasteride) within 28 days of randomization.
- Prior radiation therapy that would result in overlap of current radiation therapy fields
- Prior chemotherapy for prostate cancer
- Clinically positive lymph nodes by imaging, sampling, or dissection. Patients with lymph nodes greater than 1.5 cm on short axis will require a negative biopsy for eligibility.
- Metastatic disease, as assessed by abdominal or pelvic computed tomography (CT) or other imaging modality. Patients with 3 intermediate risk factors will require a CT abdomen/pelvis and a bone scan or PET imaging (PSMA PET/CT, fluciclovine PET/CT, etc.).
- Erectile aids other than oral phosphodiesterase (PDE)-5 inhibitors
- History of any of the following: Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), clinically significant ventricular arrhythmias, moderate or severe hepatic impairment (Child Pugh Class B or C), viral hepatitis, or human immunodeficiency virus within 6 months prior to randomization.
- Current untreated hypertension (systolic >= 160 mmHg or diastolic >= 100 mmHg). Patients with one blood pressure reading with systolic < 160 mmHg and diastolic < 100 mmHg within 90 days of registration would be eligible for study.
Individuals with a history of another malignancy are not eligible if:
- The cancer is under active treatment
- The cancer can be seen on radiology scans
- If they are off cancer treatment, but in the opinion of their oncologist, have a high risk of relapse within 5 years.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (NCI-CTCAE version 5.0 Grade 2), psychiatric illness or social situations that would limit compliance with study requirement
- Any condition that, in the opinion of the site investigator, would preclude participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bicalutamide+GnRH Agonist+Radiation Therapy
|
Bicalutamide is categorized as an antiandrogen.
Antiandrogens are substances that block the effects of testosterone.
Cancer of the prostate depends on the male hormone testosterone for its growth.
If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
In men, GnRH agonists cause the testicles to stop making testosterone.
Some GnRH agonists are used to treat prostate cancer.
Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
|
Experimental: Darolutamide+Radiation Therapy
|
Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
Darolutamide belongs to a class of drugs called androgen receptor inhibitors.
In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients with a PSA nadir <= 0.5
Time Frame: 6 months from end of treatment
|
A response is defined as a PSA nadir <= 0.5 within 6 months from end of treatment
|
6 months from end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients with good erectile function at 3 months from end of treatment
Time Frame: 3 months from end of treatment
|
Good erectile function is defined as firm enough for masturbation or foreplay' or 'firm enough for intercourse' responses to the question "How would you describe the usual quality of your erections during the past 4 weeks" on the EPIC-26 questionnaire.
|
3 months from end of treatment
|
PSA progression free survival
Time Frame: 3 years
|
PSA progression-free survival is defined as the time from randomization to PSA progression (PSA rise of 2 ng/mL above the nadir value).
|
3 years
|
Metastasis free survival
Time Frame: 3 years
|
Metastasis-free survival is defined as the time from randomization to distant metastasis (including bony or visceral) identified on imaging or pathologically, or death due to any cause, or censored at date last known alive.
|
3 years
|
Cause specific survival
Time Frame: 3 years
|
Cause specific survival is defined as the interval from the date of randomization to the date of last known follow-up alive, or the date of death from each of the following causes: prostate cancer, cardiovascular disease, other causes
|
3 years
|
To evaluate differences in long-term maintenance of erectile function
Time Frame: 3 years
|
The answers to EPIC-26 question "How would you describe the usual quality of your erections during the past 4 weeks" from treatment start to the end of follow up at three years show how erectile function has been affected over time.
|
3 years
|
Rate of Toxicity
Time Frame: 3 years
|
Toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
3 years
|
Quality of Life impact as measured by Expanded Prostate Cancer Index (EPIC)-26
Time Frame: 3 years
|
EPIC-26 is a shortened version of the EPIC questionnaire that evaluates subject's urinary incontinence, urinary irritation/obstruction, bowel, sexual, and hormonal domains.
EPIC is a robust prostate-cancer health-related QOL instrument that measures a broad spectrum of symptoms and has been widely validated.
For each domain, scales range between 0 (worse) and 100 (better).
|
3 years
|
Global health impact as measured by Patient-Reported Outcome Measurement Information System (PROMIS) Global Health Score
Time Frame: 3 years
|
PROMIS is a standardized method for measuring an individual's global health in terms of physical and mental functioning.
Scores range from 23.4 (worse) to 63.3 (better).
|
3 years
|
Memory as measured by the St. Louis University Mental Status Examination (SLUMS)
Time Frame: 3 years
|
SLUMS is a single-page exam that measures mild cognitive changes.
Scores can be divided as 0-20 (mild dementia), 21-26 (mild cognitive disorder), and 27-30 (normal).
|
3 years
|
Quality of Life impact as measured by Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Function and Satisfaction Measures (SexFS) Brief Profile Version 2.0.
Time Frame: 3 years
|
The PROMIS SexFS Brief Profile v2.0 measures a range of sexual activities, symptoms, functioning, and evaluation of experiences over the past 30 days.
Scores range from 31.6 (worse) to 62.7 (better).
|
3 years
|
Testosterone kinetics
Time Frame: 3 years
|
For arm 1, time to Testosterone Recovery is defined as the time from randomization to the date at which the testosterone level returns to a normal level on the assay used, or censored at date of last disease evaluation for those whose testosterone has not reached a normal level.
Furthermore, testosterone levels will be compared between arms 1 and 2 at EOT and yearly intervals after EOT.
|
3 years
|
Cardiovascular events
Time Frame: 3 years
|
Time to cardiovascular event is defined as the time from randomization to the date at which the first cardiovascular event occurs.
Censoring occurs at date of last disease evaluation for those who did not have a cardiovascular event.
Cardiovascular events consisting of myocardial infarction, stroke, deep venous thrombosis, or pulmonary embolism will be collected during study visits and follow-ups.
|
3 years
|
Time to re-initiation of ADT
Time Frame: 3 years
|
Time to re-initiation of ADT is defined as the time from randomization to the date at which ADT is reinitiated.
Censoring occurs at date of last disease evaluation for those who are not restarted on ADT.
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin T. King, MD, PhD, Brigham and Women's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Androgen Antagonists
- Bicalutamide
Other Study ID Numbers
- 19-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Bicalutamide
-
University of Wisconsin, MadisonPfizerTerminatedProstate CancerUnited States
-
Fox Chase Cancer CenterCompletedCancer of ProstateUnited States
-
University of L'AquilaCompletedProstate CancerItaly
-
AstraZenecaNo longer availableAdenocarcinoma of the Prostate
-
Alessa Therapeutics Inc.CompletedLower Urinary Tract Symptoms | Prostate AdenocarcinomaUnited States, Australia, New Zealand
-
Royal College of Surgeons, IrelandUniversity College Dublin; University of Oxford; University of Liverpool; University...Not yet recruitingPolycystic Ovary Syndrome | Metabolic Disease | Androgen ExcessIreland
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Withdrawn
-
SandozCompleted
-
SandozCompleted
-
Astellas Pharma IncMedivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstatic NeoplasmsUnited States, Belgium, Canada, Denmark, France, Germany, Romania, United Kingdom